We next assessed the in vivo antitumor efficacy of the humanized CD1d-Vδ2 bsTCE using whole PBMCs admixed with CCRF-CEM cells (ratio 1:2; Vγ9Vδ2-T to T-ALL ratio 1:16 and 1:47 for donor 1 and 2 respectively) in a s.c. T-ALL model in NSG mice. The gene discussed is CD1D; the disease is acute lymphoblastic leukemia.